课题基金 / 基金详情

项目摘要

项目成果

LORI SUSSEL的其他基金

相似基金

相关文献

中文摘要
翻译
中心概况 项目概要/摘要 科罗拉多丹佛大学(UC Denver)以基础、转化和临床糖尿病而闻名于世 研究和治疗1型和2型糖尿病(T1 D和T2 D)及其相关并发症。的 拟议中的科罗拉多大学糖尿病研究中心(UC Denver DRC)将加强糖尿病研究 在科罗拉多通过提供:1)国家的最先进的研究技术和专业资源,以最大限度地提高 有效和创新的研究; 2)获得患者样本和数据; 3)丰富计划,教育 和系列研讨会;和4)通过吸引新的科学家进入糖尿病领域, 试点和可行性方案。这些目标将通过提供更好的基础设施和 获得专门的试剂和资源,以及促进科学互动、研究 糖尿病治疗和治愈的发现和进展。UC Denver DRC将主要位于 在迅速发展的安舒茨医学校园(AMC)在奥罗拉,科罗拉多,其中大多数加州大学 丹佛临床和研究部门位于。这个独特的多医院和学术校园 配置允许广泛的糖尿病研究基础,目前包括88个基础,翻译, 加州大学AMC的17个部门和部门的临床科学研究人员目前带来了 糖尿病/糖尿病相关的直接费用赠款支持,个人赠款总额> 6500万美元, 1000万美元的中心和培训赠款。洛里·苏塞尔博士和医学博士Jane Reusch 科学背景和专门知识的互补领域,以监督组织和科学重点, 加州大学丹佛分校我们将实施四个生物医学研究核心,以提供尖端技术 临床资源(用于跟踪研究参与者、生物样本和数据的完全集成的数据库), 组织获取和处理(啮齿动物组织和胰岛分离,人胰岛和组织获取, 组织学服务、细胞培养库)、糖尿病建模(人干细胞衍生体外细胞和类器官 细胞和组织分析(高级显微镜、流式细胞术、专业 用于糖尿病社区的CyTOF和MIBI试剂)。UC Denver DRC还将建立一个试点项目, 可行性计划,招募年轻的教师进入糖尿病和糖尿病相关的研究,并鼓励 建立了其他领域的研究人员进入糖尿病领域。加州大学丹佛分校的院长 医学界已承诺每年补充10万美元的P&F预算,以促进糖尿病的增加。 在校园里进行研究。最后,UC Denver DRC丰富计划将促进互动 通过提供研讨会论坛交流研究成果, 提供建立合作关系的机会,并鼓励 不同的糖尿病社区。
英文摘要
CENTER OVERVIEW PROJECT SUMMARY/ABSTRACT The University of Colorado Denver (UC Denver) is world renowned for basic, translational, and clinical diabetes research and treatment of both Type 1 and Type 2 diabetes (T1D and T2D), and their related complications. The proposed University of Colorado Diabetes Research Center (UC Denver DRC) will strengthen diabetes research in Colorado by providing: 1) state-of-the-art research technologies and specialized resources to maximize effective and innovative research; 2) access to patient samples and data; 3) enrichment programs, education and seminar series to the diabetes community; and 4) by attracting new scientists into the diabetes field through the Pilot and Feasibility program. These objectives will be realized by providing improved infrastructure and access to specialized reagents and resources, and an environment that promotes scientific interactions, research discoveries, and progress towards diabetes treatment and cures. The UC Denver DRC will be primarily located on the rapidly growing Anschutz Medical Campus (AMC) in Aurora, Colorado where the majority of the UC Denver clinical and research departments are located. This unique multi-hospital and academic campus configuration allows for a broad diabetes research base, which currently includes 88 basic, translational, and clinical scientific investigators across 17 departments and divisions at UC AMC who currently bring diabetes/diabetes-related direct cost grant support totaling > $65 million in individual grants and >$14 million in center and training grants. Drs. Lori Sussel, PhD. and Jane Reusch, MD bring together complementary areas of scientific backgrounds and expertise to oversee the organization and scientific focus of the UC Denver DRC. We will implement four Biomedical Research Cores to provide cutting-edge technologies in Clinical Resources (fully integrated databases for tracking of study participants, bio-samples and data), Tissue Procurement and Processing (rodent tissue and islet isolation, human islet and tissue procurement, histology services, cell culture bank), Diabetes Modeling (human stem cell-derived in vitro cell and organoid models, gene editing), and Cell and Tissue Analysis (advanced microscopy, flow cytometry, specialized CyTOF and MIBI reagents for the diabetes community). The UC Denver DRC will also establish a Pilot and Feasibility Program to recruit young faculty into diabetes and diabetes-related research, and encourage established investigators from other fields to enter the diabetes field. The Dean of the UC Denver School of Medicine has pledged to supplement the P&F budget by $100,000 each year to promote an increased diabetes research presence on campus. Finally, the UC Denver DRC Enrichment Program will promote the interaction between diabetes researchers at UC AMC by providing seminar forums for exchange of research findings, providing opportunities to form collaborative relationships, and encouraging cross-pollination between the diverse diabetes communities.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PTPN2 mutations affect islet beta cell susceptibility in T1D
  • 批准号:
    10398956
  • 项目类别:
  • 资助金额:
    $43.02万
  • 财政年份:
    2020
  • 负责人:
    LORI SUSSEL
  • 依托单位:
PTPN2 mutations affect islet beta cell susceptibility in T1D
  • 批准号:
    10028702
  • 项目类别:
  • 资助金额:
    $42.36万
  • 财政年份:
    2020
  • 负责人:
    LORI SUSSEL
  • 依托单位:
UC Denver Diabetes Research Center
  • 批准号:
    10646143
  • 项目类别:
  • 资助金额:
    $132.72万
  • 财政年份:
    2020
  • 负责人:
    LORI SUSSEL
  • 依托单位:
PTPN2 mutations affect islet beta cell susceptibility in T1D
  • 批准号:
    10614497
  • 项目类别:
  • 资助金额:
    $43.02万
  • 财政年份:
    2020
  • 负责人:
    LORI SUSSEL
  • 依托单位:
海外基金